EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients

Takaaki Sugisawa iD, Fumi Gomi iD, Yuri Harada, Hiroko Imaizumi, Shuichiro Aoki, Akiko Miki, Maya Kishi, Tomofusa Yamauchi, Daisuke Nagasato, Yoko Ozawa, Masatoshi Haruta, Nobuhiro Kato und 13 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0325963 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, 2025. Verfasst von Takaaki Sugisawa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hyogo Medical University, Nishinomiya, Japan. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors, Macular Degeneration, Lost to Follow-Up. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To identify time-specific factors associated with loss to follow-up (LTFU) in the early to medium term after initiating anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD) in Japan.

Methods

The study had a retrospective multicenter case–control design and was performed across 16 specialist retinal facilities in Japan. Patients diagnosed with nAMD at their initial visit who initiated treatment between January 2017 and December 2020 were included. Patient characteristics were analyzed to identify factors associated with LTFU within 3 months (very early), 3 months to 1 year (early), and 1 year to 2 years (medium term) after starting treatment.

Results

Data for 2389 patients with nAMD were analyzed. The very early, early, and medium-term LTFU rates were 6.8%, 13.8%, and 21.2%, respectively. Stepwise regression analysis identified factors that were significantly associated with LTFU at a very early stage to be greater central retinal thickness at baseline and a prior treatment history, those associated with early LTFU to be worse baseline best-corrected visual acuity (BCVA), anti-VEGF treatment combined with photodynamic therapy, and a follow-up period that overlapped with the COVID-19 pandemic, and that associated with medium-term LTFU to be worse BCVA at 3 months. LTFU in any period within 3 months to 2 years was more likely in patients aged >80 years, and LTFU very early within 3 months was more likely in those aged 1 was a risk factor for LTFU within 3 months and 1 year, whereas LTFU was significantly less likely in patients with good baseline BCVA (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsMacular DegenerationLost to Follow-UpHumansFemaleMaleAgedRetrospective StudiesJapanAged, 80 and overCase-Control StudiesVisual AcuityFollow-Up StudiesMiddle AgedEast Asian People

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Hyogo Medical University, Nishinomiya, Japan.
  • Shiga University of Medical Science, Ōtsu, Japan.
  • Department of Ophthalmology, Sapporo City General Hospital, Sapporo, Japan.
  • Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
  • Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center Tokyo, Eye Center, Fujita Health University, Haneda Clinic, Tokyo, Japan.

ORCID-Profile: Takaaki Sugisawa, Fumi Gomi, Tsutomu Yasukawa, Masahiko Shimura

Zitieren

APA

Sugisawa, T., Gomi, F., Harada, Y., Imaizumi, H., Aoki, S., Miki, A., Kishi, M., Yamauchi, T., Nagasato, D., Ozawa, Y., Haruta, M., Kato, N., Matsubara, H., Yasukawa, T., Kato, A., Terasaki, H., Hirano, T., Iesato, Y., Tsujinaka, H., …, & J-CREST (Japan Clinical Retina Study) Group (2025). Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients. PLOS One. https://doi.org/10.1371/journal.pone.0325963

Vancouver

Sugisawa T, Gomi F, Harada Y, Imaizumi H, Aoki S, Miki A, et al. Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients. PLOS One. 2025. doi:10.1371/journal.pone.0325963

BibTeX
@article{Sugisawa2025,
  author = {Sugisawa, Takaaki and Gomi, Fumi and Harada, Yuri and Imaizumi, Hiroko and Aoki, Shuichiro and Miki, Akiko and Kishi, Maya and Yamauchi, Tomofusa and Nagasato, Daisuke and Ozawa, Yoko and Haruta, Masatoshi and Kato, Nobuhiro and Matsubara, Hisashi and Yasukawa, Tsutomu and Kato, Aki and Terasaki, Hiroto and Hirano, Takao and Iesato, Yasuhiro and Tsujinaka, Hiroki and Murakami, Tomoya and Mitamura, Yoshinori and Wakuta, Makiko and Kimura, Kazuhiro and Shimura, Masahiko and J-CREST (Japan Clinical Retina Study) Group, J-CREST (Japan Clinical Retina Study) Group},
  title = {Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325963}
}
Kostenlos starten →